{"entity":{"id":"nectin-4-expression","kind":"biomarker","name":"Nectin-4 expression","aka":["Nectin-4","NECTIN4 expression","Nectin-4 positive","Nectin-4 H-score"],"tldr":"Nectin-4 is expressed by almost every urothelial cancer, so enfortumab vedotin is given without a test. Nectin-4 amplification is being studied as a marker of especially strong response.","summary":"Enfortumab vedotin (Padcev) is labelled alone and with pembrolizumab for locally advanced or metastatic urothelial cancer with no Nectin-4 requirement; the pivotal EV-201 and EV-301 trials enrolled without testing after screening showed near-universal expression. Retrospective work links NECTIN4 amplification to higher response rates; a Nectin-4 PET tracer is in early trials. No approval or guideline sets a threshold.","asOf":"2026-09-23","links":[{"label":"PADCEV prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed"}],"tags":["biomarker","surface-antigen","no-threshold"],"related":["trop2-expression","fgfr3-alteration"],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["enfortumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":["ihc","gene-amplification"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"nectin4","measurement":"ihc-score","scoringRule":{"text":"The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.","quote":"PADCEV is a Nectin-4-directed antibody and microtubule inhibitor conjugate","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5631d3e-4604-4363-8f20-11dfc5a4a8ed","sourceLabel":"PADCEV prescribing information (DailyMed)"},"thresholds":[],"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"Enfortumab vedotin does not need a Nectin-4 test; the antigen is present in nearly all bladder cancers. Research is looking at whether tumours with extra copies of the Nectin-4 gene respond even better, but that is not part of routine care."},"route":"/biomarkers/nectin-4-expression/","neighbours":{"biomarker":[{"id":"fgfr3-alteration","kind":"biomarker","name":"FGFR3 alteration (mutation or fusion)","route":"/biomarkers/fgfr3-alteration/"},{"id":"trop2-expression","kind":"biomarker","name":"TROP2 expression","route":"/biomarkers/trop2-expression/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"}],"term":[{"id":"gene-amplification","kind":"term","name":"Gene amplification and copy-number change","route":"/terms/gene-amplification/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"}]}}